Chimeric antigen receptor (CAR) T cell-based therapies use genetically engineered T cells to specifically target tumor cells. This innovative therapeutic approach excites the research community and can offer a novel approach to cancer therapy.
CAR T cells are generated from patient-derived T cells (autologous) or from healthy donors (allogenic). After enrichment and genetic modification T cells are expanded ex vivo and reinfused into the patient where the CAR T cells bind to the specific surface antigen and kill the tumor cell.
To develop CAR T cell therapies, it is necessary to include research of:
Our goal is it to support you at every step of your workflow to simplify the translation of your research workflow using RUO products into GMP manufacturing using the CliniMACS Prodigy® in combination with MACS® GMP reagents. This approach reduces expenditures and time by minimizing process re-development and re-optimization, thereby streamlining the process for optimal efficiency.
Our innovative research solutions include isolation of the best-performing T cell subtypes using MACS® Technology, reliable activation of T cells using T Cell TransAct™, efficient gene delivery and expansion methods to obtain fully functional CAR T cells, reliable and reproducible in process control (IPC) and quality control (QC) to monitor the CAR T cell manufacturing process, e.g., by flow cytometric surface marker analysis or cytokine profiling.
Benefit from our expertise and learn how we can support all of your CAR T cell research needs.
Seems like you are coming from USA!
Do you want to visit our website in your country?